

VOLUMEN XLV

NUMERUS Suppl. 2

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2017

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Danko Velimir Vrdoljak

Editors

Lidija Beketić-Orešković, Zvonko Kusić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Hrvoje Šobat – Radiation Oncology

Technical Editor

Anica Vrdoljak

Editorial Board

Gordana Brozović, Krešimir Gršić, Željko Herceg, Nada Kraljević, Ljiljana Mayer, Ivan Milas, Aleksandar Milenović, Marija Milković Periša, Marija Pastorčić-Grgić, Vesna Pavlica, Mario Puljiz, Vesna Ramljak, Andrej Roth, Sanda Šitić, Ljiljana Štefančić, Tiha Vučemilo

Editorial Council

D. Babić (Zagreb, Croatia), V. Banović (Zagreb, Croatia), A. Bolanča (Zagreb, Croatia), D. Chudy (Zagreb, Croatia), M. Čorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), N. Đaković (Zagreb, Croatia), D. Eljuga (Zagreb, Croatia), G. Fisher (Stanford, USA), M. Gamulin (Zagreb, Croatia), D. Gugić (Osijek, Croatia), H. Haler (Rijeka, Croatia), J. Jassem (Gdansk, Poland), A. Juretić (Zagreb, Croatia), A. Karamarković (Belgrade, Serbia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), S. Levanat (Zagreb, Croatia), D. Marčinko (Zagreb, Croatia), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S. Ž. Pavletić (Bethesda, USA), R. Pirker (Wien, Austria), M. Solarić (Zagreb, Croatia), B. I. Šikić (Stanford, USA), E. Vrdoljak (Split, Croatia), M. Zovak (Zagreb, Croatia)

Indexed in EMBASE/Excerpta Medica

Editorial Office:
LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia, P.O. Box 427,
Phone (385 1) 37 83 522, Fax (385 1) 37 75 536
Web site: <http://hrcak.srce.hr/libri-oncologici>
e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 60 HRK. Annual subscription rates in Croatia: 300 HRK + VAT for institutions, 150 HRK + VAT for individuals and 60 HRK + VAT for students, to be remitted with Hrvatska poštanska banka, account HR31 2390 0011 1004 1610 4 Ref.No.3 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska poštanska banka, IBAN: HR31 2390 0011 1004 1610 4 (Ref.No.3), BIC code: HPBZHR2X (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb



**9. godišnji sastanak
Hrvatskog društva za internističku onkologiju
Hrvatskog liječničkog zbora
s međunarodnim sudjelovanjem**

**11. radni sastanak
Sekcije za onkološku farmaciju Hrvatskog farmaceutskog društva
s međunarodnim sudjelovanjem**

**Hrvatsko društvo za internističku onkologiju Hrvatskog liječničkog zbora
Sekcija za onkološku farmaciju Hrvatskog farmaceutskog društva**

20. – 21. listopada 2017., hotel "Turist", Varaždin, Hrvatska

**9th Symposium and Annual Meeting of Croatian Society
for Medical Oncology of Croatian Medical Association
with International Participation**

**11th Meeting of Oncology Pharmacy Section
of Croatian Pharmaceutical Society
with International Participation**

**Croatian Society for Medical Oncology, Croatian Medical Association
Oncology Pharmacy Session, Croatian Pharmaceutical Society**

20th – 21st October 2017, hotel "Turist", Varaždin, Croatia

Supplement editors:

Damir Vrbanec
Ana Tečić Vuger

Zagreb, Croatia
January 2018

ORGANIZER

Croatian Society for Medical Oncology, Croatian Medical Association
Croatian Medical Association
Section for Oncology Pharmacy, Croatian Pharmaceutical Society
Croatian Pharmaceutical Society
Faculty of Pharmacy and Biochemistry
European Society for Oncology Pharmacy – ESOP
Croatian Pharmacy Chamber

Chair of the Organizing Committee

Damir Vrbanec

Organizing Committee

<i>Dahna Arbanas</i>	<i>Vesna Pavlica</i>
<i>Ivan Bilić</i>	<i>Stjepko Pleština</i>
<i>Borislav Belev</i>	<i>Marko Skelin</i>
<i>Zlatko Dembić</i>	<i>Robert Šeparović</i>
<i>Natalija Dedić Plavetić</i>	<i>Darko Takač</i>
<i>Renata Dobrila Dintinjana</i>	<i>Ana Tečić Vuger</i>
<i>Davorin Herceg</i>	<i>Dragan Trivanović</i>
<i>Martina Kranjec Šakić</i>	<i>Željko Vojnović</i>
<i>Marta Kučan</i>	<i>Sanda Vladimir – Knežević</i>
<i>Sven Kurbel</i>	<i>Damir Vrbanec</i>
<i>Klaus Meier</i>	<i>Darko Županc</i>

Sponsors & Donators

Roche
Astellas
Bayer
Pliva
Sandoz
Abbott
Amgen
AstraZeneca
Celgene
Lilly
GM PharmaZagreb d.o.o.
Janssen
Krka
Medical Intertrade
Merck
MSD
Novartis
Pfizer
Sanofi Genzyme
Servier
Stada

Contents

ORAL PRESENTATION

Silovski T.	
S1 - What's new in neoadjuvant treatment of breast cancer?	3
Tečić Vuger A, Šeparović R.	
S2 - Genetic analysis in breast cancer	4
Čonkaš M.	
S3 - News in the neoadjuvant therapy of rectal cancer	5
Silovski T.	
S4 - ESMO Highlights	6
Kurbel S, Mihaljević S.	
S5 - Logic in interpreting clinical trial results: Comparison between inductive and deductive reasoning	7
Gnjidić M.	
S6 - News in the treatment of urogenital cancers	8
Dobrila Dintinjana R, Redžović A.	
S7 - Personalised therapy of hepato-pancreato-biliary malignancies	9
Belev B.	
S8 - News in gastrointestinal oncology	10
Kulić A.	
S9 - Metabolomics-metabolic phenotype of cancer	11
Kurbel S, Dmitrović B.	
S10 - Emerging importance of Thrombospondin-1 and Endothelin-1 in cancer development and growth	12
Dedić Plavetić N.	
S11 - Novel treatment strategies in breast cancer	13
Ladenhauser T.	
S12 - Dose Dense Chemotherapy in Adjuvant Treatment of Early Breast Cancer - Pro Arguments	14

Budisavljević A.	
S13 – Dose dense chemotherapy, is there a catch?	15
Pavlović M.	
S14 - Surgery after neoadjuvant treatment for rectal cancer	16
Prejac J.	
S15 - Watch and wait approach to rectal cancer	17
Vrbanec J.	
S16 - Role of Family medicine physician in treatment of oncologic patients	18

POSTERS

Krpina K, Drpa G, Budimir B, Ćuk B, Lampalo M, Kukulj S, Jakopović M, Samaržija M.	
P1 - ALK-rearranged lung non small cell carcinoma	
with CNS metastasis responding to alectinib: a case report	21
Lonjak N, Bajić Ž, Vuković P, Raguž J, Nikles I, Badžek I, Tečić Vuger A,	
Pavlović M, Šeparović R.	
P2 - Predictors of response to neoadjuvant treatment in estrogen receptor-positive	
breast cancer at the University Hospital for Tumors, Sestre milosrdnice	
University Hospital Center; a retrospective cohort study	22
Jurčić P.	
P3 - Treatment of platinum- and cetuximab-refractory hypopharyngeal cancer;	
a case report	23
Maloševac S, Popek I, Brkić I, Šeparović R.	
P4 - Public health significance of lung cancer in Sisak, Croatia-Moslavina County . . .	24
Mandić S, Ćuk B, Tolj I, Bilobrk J, Radić P, Jakić-Razumović J, Dedić Plavetić N, Vrbanec D.	
P5 - Clinical and molecular characteristics of triple-negative early breast	
cancer patients in University Hospital Centre Zagreb	25
Vuković P, Badžek I, Raguž J, Lonjak N, Nikles I, Šeparović R.	
P6 - Are we burnt out from our work? - signs of burnout	
in Medical Oncology residents	26
Badžek I, Vuković P, Raguž J, Nikles I, Lonjak N, Šeparović R.	
P7 – Job satisfaction in Medical Oncology residents	27
Krstić C, Lonjak N, Vuković P, Šahbazović A, Raguž J, Šeparović R.	
P8 – Our experience in management of metastatic HER2-positive breast cancer	
with trastuzumab emtansine	28
Radmilović Varga Lj, Ječmenica D, Kolarić V.	
P9 – Survival rates as moving targets: lung cancer target therapy amplifies	
survival expectations	29

Ćuk B, Krpina K, Budimir B, Drpa G, Kukulj S.	
P10 – An unusual case of rhabdomyosarcoma as anterior mediastinal mass, in the clinical presentation of Superior Vein Cava Syndrome	30
Maloševac S, Ćuk B, Mandić S, Pacić-Hardi N.	
P11 - Pericardial effusion as the first manifestation of locally advanced pulmonary adenocarcinoma in emergency services; case report	31
Prejac J, Goršić I, Vidović M, Golem H, Kekez D, Librenjak N, Pleština S.	
P12 - Comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of pancreatic adenocarcinoma in the University Hospital Centre Zagreb	32
Radmilović Varga Lj, Križić M, Kulić A, Podolski P, Bašić Koretić M, Herceg D, Vrbanec D, Dedić Plavetić N.	
P13 – Do patients from routine practice reflect clinical study population? First line treatment of metastatic HER2 positive breast cancer in University Clinical Centre Zagreb	33
Reljić D, Paić M, Grubišić-Čabo R, Bošnjak M, Mojsović A, Grubišić-Čabo F.	
P14 - The meaning od positive surgical margins in patients whom partial nephrectomy has been made bacause of kindey cancer	34
Nalbani M, Simetić L.	
P15 - Doege-Potter syndrome: hypoglycemia secondary to solitary fibrous tumors; case report	35
Nikles I, Veliki Dalić I, Nikles S, Vuković P, Raguž J, Lonjak N, Šeparović R.	
P16 - Prognostic value of lymphovascular invasion (LVI) in breast cancer patients with clinically node-negative axilla	36
Raguž J, Vuković P, Nikles I, Lonjak N, Krstić C, Šahbazović A, Bilić Knežević S, Miletić M, Šeparović R.	
P17 – Mobile palliative teams and patient content with palliative care - experience from University hospital for tumors	37
Tomljanović I, Bukovica A, Skočilić I, Belac-Lovasić I.	
P18 – Case report: Patient with HER2 positive breast cancer and luminal A metastases in the scalp	38
Kovač M.	
P19 – Topics patients would like to confer about with an oncologist before the onset of systemic treatment	39
Kardum Fučak I.	
P 20 – A case report: Occurrence of IgM mediated - autoimmune anemia after 1st application of taxane in neoadjuvant setting for hormone receptor positive, HER2 negative locally advanced breast cancer	40
Bitar L, Seiwerth F, Krpina K, Koršić M, Kukulj S, Pleština S, Samaržija M, Jakopović M.	
P 21 – Osimertinib in the treament of patients with T790M mutation	41

Tečić Vuger A, Lonjak N, Vuković P, Pavlović M, Šeparović R.	
P 22 – The Correlation between findings of preoperative MR and definitive PHD of the primary tumor after neoadjuvant treatment in breast cancer patients	42
Demser M, Belev B.	
P23 – Evaluation of <i>burn-out syndrome</i> in oncology employees	43
Sirotković-Skerlev M, Dedić Plavetić N, Vrbanec D, Bilić I, Belev B, Sedlić F, Kovač Z, Kulic A.	
P 24 – Analisys of circulating leptin in breast cancer patients	44
Kamenečki V, Lonjak N, Tečić Vuger A, Šeparović R.	
P 25 - Influence of upper-body function on the quality of life in patients treated with adjuvant systemic antineoplastic treatment at the University Hospital for Tumors	45
A U T H O R I N D E X	46